Brokers Issue Forecasts for CG Oncology FY2030 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for CG Oncology in a report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado expects that the company will earn $4.42 per share for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.57). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.07 million.

A number of other equities research analysts have also recently commented on CGON. Guggenheim initiated coverage on CG Oncology in a research note on Tuesday, October 7th. They issued a “buy” rating and a $90.00 price target for the company. Truist Financial upped their price objective on shares of CG Oncology from $62.00 to $66.00 and gave the company a “buy” rating in a report on Friday, January 9th. The Goldman Sachs Group reiterated a “buy” rating and issued a $82.00 target price on shares of CG Oncology in a research note on Monday, January 12th. Wall Street Zen raised shares of CG Oncology from a “sell” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, Wedbush began coverage on shares of CG Oncology in a research note on Thursday, December 11th. They set an “outperform” rating and a $70.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $67.83.

CG Oncology Price Performance

CG Oncology stock opened at $53.84 on Wednesday. CG Oncology has a 1-year low of $14.80 and a 1-year high of $57.88. The business has a fifty day moving average price of $45.12 and a 200-day moving average price of $37.90. The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of -26.39 and a beta of 1.35.

Institutional Investors Weigh In On CG Oncology

Several hedge funds have recently added to or reduced their stakes in the business. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CG Oncology during the 4th quarter valued at about $27,000. Winthrop Capital Management LLC acquired a new stake in CG Oncology during the second quarter worth about $38,000. Strengthening Families & Communities LLC purchased a new position in CG Oncology during the third quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in CG Oncology by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after acquiring an additional 433 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James Mulay sold 11,145 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. Additional details regarding this sale are available in the official SEC disclosure.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.